TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Other Events
Item 8.01
| Other Events. |
On April 13, 2017, Tonix Pharmaceuticals Holding Corp. (the
Company) issued a press release announcing the closing of the
full exercise of the over-allotment option by the underwriters of
the Companys previously announced underwritten public offering
with respect to an additional 270,000 shares of the Companys
common stock.
A copy of the press release that discusses this matter is filed
as Exhibit 99.01 to, and incorporated by reference in, this
report. The information in this Current Report is being furnished
and shall not be deemed filed for the purposes of Section 18 of
the Securities Exchange Act of 1934 or otherwise subject to the
liabilities of that Section. The information in this Current
Report shall not be incorporated by reference into any
registration statement or other document to the Securities Act of
1933, except as shall be expressly set forth by specific
reference in any such filing.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| 99.01 |
Press release, dated April 13, 2017, issued by Tonix Pharmaceuticals Holding Corp.* |
* Furnished herewith.
TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Recent Trading Information
TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) closed its last trading session down -0.02 at 4.73 with 793,261 shares trading hands.
